Table 4.
Number and description of patients’ reported and observed adverse experiences during the period from treatment to evaluation. Per protocol population
| Methylprednisolone n = 27 n (%) | Saline n = 25 n (%) | |
|---|---|---|
| Any adverse eventa | 17 (63) | 7 (28) |
| Common cold/influenza | 2 (7) | 1 (4) |
| Treatment‐related adverse eventa | 16 (59) | 6 (24) |
| Increase in pain | 9 (33) | 4 (16) |
| Transient paraesthesia of the eyelid | 3 (11) | 0 (0) |
| Transient numbness | 2 (7) | 0 (0) |
| Rash/local allergic reaction | 2 (7) | 0 (0) |
| Difficulties in opening the jaw | 2 (7) | 0 (0) |
| TMJ sounds | 2 (7) | 0 (0) |
| Teeth do not fit together | 1 (4) | 1 (4) |
| Headache | 1 (4) | 1 (4) |
TMJ, temporomandibular joint.
Treatment‐emergent adverse events with onset on the day of commencing treatment until the evaluation visit.
a
Rated by the investigator as probably or definitely related to the intervention.